****** Glaucoma Market To Register A Stout Growth By 2026 | Data Bridge Market Research

Market Analysis: ****** Glaucoma Market

****** Glaucoma Market is expected to rise gradually to an estimated value of USD 3.95 billion by 2026, registering a CAGR of 4.3% in the forecast period of 2019-2026 with the annual sales of USD 2.82 billion in the year 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Few of the major competitors currently working in the glaucoma market are AERIE PHARMACEUTICALS, INC. (US), ALLERGAN (Ireland), Bausch & Lomb Incorporated (US), www.inotekcorp.com (US), Merck & Co. Inc. (US), Pfizer Inc. (US), Fera Pharmaceuticals (US), Teva Pharmaceutical Industries Ltd. (Israel), EyePoint Pharmaceuticals (US), Amorphex Therapeutics LLC. (US), ellex (Australia), Quantel (UK), Lumenis (Israel), Acorn Biomedical, Inc (US), Acucela Inc. (Japan), Alcon (US), Astellas Pharma Inc. (Japan), Bayer AG (Germany), BioAxone (US), Novartis AG (Germany) and few among others.

Get Sample Analysis of ****** Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=******-glaucoma-market

Market Definition: ****** Glaucoma Market

Glaucoma is a condition in which the intra-ocular pressure increases due to which aqueous humor exits slowly through the trabecular meshwork that causes damage to optic nerve and results into vision loss. It can be open angle glaucoma or closed angle glaucoma.

According to Santen Pharmaceutical Co., Ltd. Annual Report 2017, , around 80.4 million people are affected by glaucoma, and half of these cases could have been avoided with the availability of proper medical treatment for healthcare procedures. This significant number is expected to act as a driver to the market growth.

Market Drivers

  • According to The International Agency for the Prevention of Blindness, 3 million people lost their vision due to glaucoma, in 2015. Increase in the incidence rate of blindness is expected to be the major driving factor for growth of the market.
  • Government initiatives and awareness programs for better health of population will drive the growth of market.
  • Postoperative complications resulting after glaucoma surgery will act as a driver.

Market Restraints

  • Strict government regulations and approvals
  • Better efficacy and efficiency of current drugs, especially prostaglandin analogs and carbonic anhydrase inhibitors, have set barriers for development of new therapy options.
  • The adverse effects of glaucoma medications will hinder the growth of the glaucoma therapeutic market.

Segmentation: ****** Glaucoma Market

By Indication

  • Closed Angle Glaucoma (CAG)
  • Open Angle Glaucoma (OAG)
  • Secondary Glaucoma
  • Congenital Glaucoma
  • Other

By Drug Class

  • Prostaglandin Analogs (PGAS)
  • Alpha Agonist
  • Beta Blockers
  • Cholinergic Drugs
  • Carbonic anhydrase inhibitors
  • Others

By Surgery

  • Laser Iridotomy
  • Laser Trabeculoplasty
  • Aqueous Shunt Surgery
  • Peripheral Iridotomy
  • Others

By End-User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
    • US.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific
  • Middle East & Africa
    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=******-glaucoma-market

Key Developments in the Market:

  • On 12th March 2019, Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Rocklatan (netarsudil and latanoprost ophthalmic solution) for the indication of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. This innovative once daily fixed dose combination will help the company to grow.
  • On 18th December, 2017, Aerie Pharmaceuticals announced the U.S. FDA approval of Rhopressa (netarsudil ophthalmic solution) for the lowering of elevated intraocular pressure in patients with ocular hypertension. That makes the company a ****** leader in glaucoma market.

Competitive Analysis: ****** Glaucoma Market

****** glaucoma market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of glaucoma market for ******, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.